Skip to main content
Equibles
TNXP logo

TNXP · Tonix Pharmaceuticals Holding Corp. · Metrics

Track TNXP — free

Use TNXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TNXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.17 +0.04 (+0.78%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$88.67M
Shares
17.15M
Volume · Oct 23 754.75K Avg daily vol (3M) 638.76K

TNXP metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.17
Market cap
$88.67M

Price action

20 metrics
Price change (1W)
-14.4%
Price change (30D)
-47.6%
Price change (3M)
-47.7%
Price change (6M)
-59.0%
Price change (YTD)
-66.9%
Price change (1Y)
-72.2%
Trailing year
Price change (5Y)
—
52-week high
$20.35
52-week low
$5.13
Change from 52-week high
-74.6%
Change from 52-week low
+0.8%
Annualized volatility
71.7%
Annualized volatility (3M)
61.1%
Beta
1.9
RSI (14D)
14.1
Price vs SMA 50
-49.7%
Price vs SMA 200
-59.4%
Avg volume (3M)
638,759
Relative volume
1.2
Average dollar volume
$6.04M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
17.15M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-3.0×
EV / EBITDA
—
EV / EBIT
—
P / sales
3.0×
reciprocal yield 32.8%
P / book
0.4
reciprocal yield 250.7%
FCF yield
-178.3%
TTM · current market cap
Buyback yield
15.5%
P / FCF
—
P / operating cash flow
—
Earnings yield
-180.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.5×
reciprocal yield 15.3%
EV / revenue historical average (5Y)
6.5×
reciprocal yield 15.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
15.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-21

Profitability

9 metrics
Gross margin
83.8%
Operating margin
-568.4%
Trailing 12 months
Net margin
-548.6%
Gross profit (TTM)
$24.40M
Operating profit (TTM)
−$165.43M
Net income (TTM)
−$159.67M
Trailing 12 months
Diluted EPS (TTM)
$-13.24
FCF margin
-543.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$19.17

Growth

11 metrics
Revenue growth YoY
+577.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$29.10M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+127.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-71.8%
Return on assets
-62.8%
Debt / equity
0.0
Current ratio
6.6
EBITDA (TTM)
−$163.34M
Free cash flow (TTM)
−$158.11M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$176.23M
Latest balance sheet
Cash & equivalents
$176.23M
Total assets
$254.09M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$152.99M
Capital expenditures (TTM)
$5.12M
R&D (TTM)
$63.86M
SG&A (TTM)
$125.96M
Stock compensation (TTM)
$7.94M
R&D / revenue
219.4%
Stock compensation / revenue
27.3%

Ownership (13F)

9 metrics
13F filers
103
13F filer change QoQ
+21
Institutional ownership
57.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
30.6%
Private-fund adviser ownership
29.9%
Active holders' share change QoQ
+150.4%
Holder tenure
5.4
Price vs estimated holder cost
-10.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.0%

Short interest

3 metrics
Short interest
17.1%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
$40,180
Insider-sentiment score
82 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1430306 CUSIP 890260839 13F (30d) 16 filings 16 filers Visit website Investor relations